Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2021 Filed Dec 10, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,851 | $88.62 | $252,656.76 |
DisclosureSEC source: 0001214659-21-012990 · marketforms-54594.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,013 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $84.83 to $90.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,100 | $84.31 | $92,742.98 |
DisclosureSEC source: 0001214659-21-012990 · marketforms-54594.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,864 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $83.82 to $84.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,009 | $83.03 | $249,846.00 |
DisclosureSEC source: 0001214659-21-012990 · marketforms-54594.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,964 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $82.55 to $83.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,960 | $5.95 | $41,412.00 |
DisclosureSEC source: 0001214659-21-012990 · marketforms-54594.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:36 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,829 | $110.62 | $312,943.98 |
DisclosureSEC source: 0001214659-21-012190 · marketforms-54368.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,013 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,440 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-011963 · marketforms-54267.xml · derivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,853 Underlying: Common Stock · 10,440 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,676 | $115.68 | $772,309.05 |
DisclosureSEC source: 0001214659-21-011963 · marketforms-54267.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $115.27 to $116.11 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,764 | $114.73 | $431,855.01 |
DisclosureSEC source: 0001214659-21-011963 · marketforms-54267.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,518 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $114.10 to $115.06 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 10,440 | $5.95 | $62,118.00 |
DisclosureSEC source: 0001214659-21-011963 · marketforms-54267.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,501 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · derivative · entry 9 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,513 Underlying: Common Stock · 1,501 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,501 | $139.39 | $209,217.79 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $139.04 to $139.82 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,501 | $8.82 | $13,238.82 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,208 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · derivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,014 Underlying: Common Stock · 8,208 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,208 | $138.77 | $1,139,037.29 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $138.75 to $138.775 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 8,208 | $8.82 | $72,394.56 |
DisclosureSEC source: 0001214659-21-011292 · marketforms-54170.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,584 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · derivative · entry 16 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,222 Underlying: Common Stock · 5,584 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,220 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · derivative · entry 15 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,293 Underlying: Common Stock · 5,220 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,534 | $134.34 | $206,080.63 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $134.055 to $134.655 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 900 | $133.38 | $120,042.99 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,376 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.89 to $133.595 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,884 | $132.25 | $249,165.41 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 9 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,276 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.865 to $132.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,007 | $131.35 | $394,980.58 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,160 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.85 to $131.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,165 | $130.24 | $542,438.35 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,167 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.83 to $130.795 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,718 | $129.20 | $221,973.33 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,332 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $128.82 to $129.67 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,584 | $8.82 | $49,250.88 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,220 | $5.95 | $31,059.00 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,866 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · derivative · entry 14 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,806 Underlying: Common Stock · 8,866 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 525 | $129.95 | $68,226.27 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,246 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.87 to $130.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,641 | $129.00 | $1,114,677.77 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,771 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $128.75 to $129.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 8,866 | $8.82 | $78,198.12 |
DisclosureSEC source: 0001214659-21-011157 · marketforms-54143.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 936 | $117.41 | $109,895.76 |
DisclosureSEC source: 0001214659-21-010742 · marketforms-54064.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,546 F4 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e) Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,740 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-010742 · marketforms-54064.xml · derivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,513 Underlying: Common Stock · 1,740 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 382 | $121.36 | $46,360.82 |
DisclosureSEC source: 0001214659-21-010742 · marketforms-54064.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,482 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $121.305 to $121.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,358 | $120.62 | $163,801.82 |
DisclosureSEC source: 0001214659-21-010742 · marketforms-54064.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,864 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.235 to $120.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,740 | $5.95 | $10,353.00 |
DisclosureSEC source: 0001214659-21-010742 · marketforms-54064.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-061025 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. F1 · derivative.expiration_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 23:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,286 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001209191-21-061025 · doc4.xml · derivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 Underlying: Class A Common Stock · 22,286 shares Expires 2031-10-14 F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,740 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-010532 · marketforms-54020.xml · derivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,253 Underlying: Common Stock · 1,740 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,740 | $110.16 | $191,681.36 |
DisclosureSEC source: 0001214659-21-010532 · marketforms-54020.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,482 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $110 to $110.63 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,740 | $5.95 | $10,353.00 |
DisclosureSEC source: 0001214659-21-010532 · marketforms-54020.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,740 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · derivative · entry 12 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,993 Underlying: Common Stock · 1,740 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 983 | $101.37 | $99,650.64 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,482 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $101.16 to $101.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 757 | $100.45 | $76,042.09 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,465 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $100.05 to $101.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,740 | $5.95 | $10,353.00 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,960 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · derivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,733 Underlying: Common Stock · 6,960 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 100 | $98.68 | $9,867.50 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,482 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,920 | $97.85 | $285,719.66 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,582 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $97.54 to $98.35 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,940 | $96.88 | $381,717.84 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,502 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $96.535 to $97.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,960 | $5.95 | $41,412.00 |
DisclosureSEC source: 0001214659-21-010358 · marketforms-53994.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 661 | $105.50 | $69,735.50 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,482 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,143 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.